If you know of an event that you feel should be listed on our calendar, please send details to info@mjdispensaries.com ~Thank You

Latest Headlines and Information

Showing posts with label cannabinoids. Show all posts
Showing posts with label cannabinoids. Show all posts

Tuesday, November 16, 2010

NEWS: Cocoa and the Search for Dietary Cannabinoids

Since the discovery of cannabinoid compounds outside of the Cannabis plant, researchers have continued bio-prospecting other fruits and vegetables for cannabinoid activity. Current research suggests new sources of plant cannabinoids may continue to be found.

Some of the results have been promising, for instance polyphenols found in tea may activate cannabinoid receptors and there is even a dietary cannabinoid that is found in nearly all edible plants. Additionally, the smelly molecules found in plants called terpenes are common across different species. Terpenes or terpenoids found on the Cannabis and other plants may also have some interesting effects in humans.

The first strong evidence of cannabinoids as part of the human diet began in 1996. Nature published an article by Emmanuel di Tomaso, Massimilliano Beltramo, and Daniele Piomelli describing the discovery of endocannabinoids in chocolate. The authors were excited as they thought the presence of these endocannabinoids could explain the "chocolate craving, common of western society' and "the association of chocolate craving with drug-induced psychoses."

``There is something about chocolate that people like it way beyond its texture, taste and smell,'' said Daniele Piomelli of the Neurosciences Institute.

Endocannabinoids are lipids that are made by our body.The active constituents in Cannabis mimic these compounds by activating the same receptors as endocannabinoids. Endocannabinoids and their receptors appear to have important roles in bone health and depression.

Endocannabinoids that are made by the body include 2-AG, Oleamide, and Anandamide. Recent evidence suggests that the endocannabinoid system is important for healthy development.Interestingly, 2-AG is found in significantly high levels in human breast milk.

These lipids act upon the cannabinoid receptors. There are two types of cannabinoid receptors. The type 1 receptor is the one of the most abundant receptors in the human brain and is found on nerves throughout the body. The type 2 receptor is abundantly expressed on immune cells.

Piomelli and colleagues thought the fat in chocolate might contain lipids that were similar to Anandamide or other endocannabinodis. The researchers found three structurally related compounds known as N-acylethanolamines (NEAs). The authors demonstrated that the NEAs could directly and indirectly activate cannabioid receptor. The NEAs can activate cannabinoid receptors by preventing the degradation of Anandamide, like Aspirin, thus raising the levels of endocannabinoids leading to increased receptor activity.

However, the results needed to be confirmed in an animal model or in humans, to determine if these cocoa compounds are available in high enough amounts to cause an effect.

So, in 1998 Nature again published findings on cannabinoids in chocolate. This time researchers tested the effects of orally administered cannabinoids in a model of mouse behavior. Some of the compounds were found to cause an effect at high doses but the authors determined that only about 1-5% of these cannabinoids are extracted from dietary sources. Thus the possibility of achieving a cannabis-like effect is small unless these compounds can act synergistically.

In response to this 1998 article, Massimiliano Beltramo and Daniele Piomelli reviewed the research and concluded"...although the results of DiMarzo et al.’s study will reassure manufacturing companies that the risks of chocolate consumption do not include cannabis-like intoxication, they provide little new information on the intriguing psychopharmacology of cocoa. This substance remains, in R. J. Huxtable’s apt words, “more than a food but less than a drug.”

Source: Examiner

Thursday, September 16, 2010

NEWS: Is Big Pharma Courting Widescale Cannabis Distribution?

When Professor Roger Pertwee announced to the world 'cannabis should be sold in shops ' it was quickly the talk of social networks facebook and twitter.

Here, was a respected academic in his field, promoting the harm recuction possibilities of doing away with the prohibition of cannabis, and in doing so he was also rubbishing the 'public health' message behind government generated anti-cannabis propoganda.

Not only a respected academic, but THE respected academic in cannabis research.

Professor Pertwee is said to be a 50 percent share in the partnership which actually discovered THC, the active component in cannabis. But maybe '50% share' was a bad use of verbage? Or was it?

All of a sudden the realisation of what looks like a clumsily implemented PR campaign becomes apparent.

The mist clears..and the reasons an educated and wholly qualified academic was stumbling and bumbling over his lines (it might work, it won't work) is clear for all to see.
In 2003 Professor Roger Pertwee was appointed as 'Head of Pharmacology' at UK cannabis pioneers GW Pharmaceuticals.

GW Pharmaceuticals manufacture the cannabis based medicine 'Sativex' which is commanding so many column inch's in today's press, (its a licensed medicine, although no-one on the NHS is allowed to have it - weird huh?).

They are also the only commercial enterprise in the United Kingdom which is ideally positioned to take advantage of a relaxation in the UK's frankly ridiculous cannabis laws as they are already geared up with tens of thousands of cannabis plants already growing, today, under glass.

In an announcement dripping with platitudes for Professor Pertwee's work , GW Pharma announced to the world, "Professor Pertwee is one of the world's leading cannabinoid scientists, having researched this area for over 30 years, and is the author of over 220 publications. He is a Past President of the International Cannabinoid Research Society and is frequently consulted about the therapeutic potential of cannabis and cannabinoids by parliamentary committees as well as leading medical organisations.

So no one is doubting Professor Pertwee's credentials, and at the time the good prof himself was clearly on a scientific mission. But has the professor made a deal with the devil in securing funding for further cannabinoid research?

Professor Pertwee said of the appointment, "The prospect of exploring the pharmacological actions of individual plant cannabinoids, separately and in combination, is exciting for both scientific and clinical reasons. The setting up of the Institute [Cannabinoid Research Institute] will greatly facilitate fundamental research into the pharmacology of plant cannabinoids and the exploitation of these constituents of cannabis as medicines."

Exploitation?

Thats right. No one is going to spend millions of pounds researching something without there being some form of payback on the horizon. Thats called enterprise.

Dr Geoffrey Guy, Executive Chairman of GW, commented, "It is our aim that GW should occupy the centre ground of cannabinoid science. We are therefore building a bridge between commercial enterprise and academia by establishing the Cannabinoid Research Institute .

So it would seem as far back as 2003 (coincidentally the year Labour Home Secretary David Blunkett decided to declassify cannabis from B to C), GW Pharmaceuticals were already looking towards a day in the not too distant future when democracy (remember that Mr Cameron?) would force cannabis onto the ballot.

Well that day has come. Proposition 19 hits the voting booth's in California come November 2010, when Governor Arnold Schwarzenegger will allow the electorate to decide how cannabis stands in the eyes of the law.

Here in the UK the blue-print for a mass-production facility already exists.

The only question which remains, is whether or not the average British toker is going to support a mass-produced product over something they can grow themselves for a few pounds invested at the local garden centre.

One would suspect not.

Source: PR Cannazine


Share

Thursday, July 22, 2010

NEWS: Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse.

The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors.

We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of cannabinoid targets in a series of 87 human breast tumors.

Results: Our results show that both Delta9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist, reduce tumor growth, tumor number, and the amount/severity of lung metastases in MMTV-neu mice.

Histological analyses of the tumors revealed that cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis, and impair tumor angiogenesis. Cannabinoid antitumoral action relies, at least partially, on the inhibition of the pro-tumorigenic Akt pathway.

We also found that 91% of ErbB2-positive tumors express the non-psychotropic cannabinoid receptor CB2.

Conclusions: Taken together, these results provide a strong preclinical evidence for the use of cannabinoid-based therapies for the management of ErbB2-positive breast cancer.

Author: Maria CaffarelClara AndradasEmilia MiraEduardo Perez-GomezCamilla CeruttiGema Moreno-BuenoJuana FloresIsabel Garcia-RealJose PalaciosSantos ManesManuel GuzmanCristina Sanchez
Credits/Source: Molecular Cancer 2010, 9:196

Source: 7th Space Interactive

Share

TheCannabisChef.com - The Art and Science of Cooking with Cannabis (Medicinal Marijuana)

Thursday, April 29, 2010

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

C. H. Ashton, P. B. Moore, P. Gallagher, A. H. Young

Department of Psychiatry, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder were found to exist, although some patients claim that cannabisrelieves symptoms of mania and/or depression. The cannabinoids DELTA 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects. Pure synthetic cannabinoids, such as dronabinol and nabilone and specific plant extracts containing THC, CBD, or amixture of the two in known concentrations, are available and can be delivered sublingually. Controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.

Journal of Psychopharmacology, Vol. 19, No. 3, 293-300 (2005)
DOI: 10.1177/0269881105051541